Literature DB >> 9721872

Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.

Y H Ling1, Y Yang, C Tornos, B Singh, R Perez-Soler.   

Abstract

The c-Mos gene product is a component of the cytostatic factor and, as such, stabilizes the maturation-promoting factor causing cell-cycle blockade at metaphase II in unfertilized eggs. The potential role of c-Mos in regulating cell-cycle progression and cell death in somatic cells remains unknown. We studied whether paclitaxel-induced M-phase arrest and apoptosis are associated with c-Mos gene expression and activation in SKOV3 ovarian carcinoma cells. The first cellular effect observed with continuous exposure to 50 ng/ml paclitaxel (ID50) was mitotic arrest with an increase in the accumulation of cyclin B1 and stimulation of cdc2/cyclin B1 kinase in a time-dependent manner during a 36-h incubation. DNA fragmentation determined by agarose gel electrophoresis and quantitation of [3H]thymidine-prelabeled genomic DNA was a later event, first detected at 24 h and peaking at 48 h (later time points were not studied). Induction of the c-Mos gene expression and activation were determined by Western blot analysis, immunoprecipitation using a polyclonal anti-mos antibody, reverse transcription-PCR assay, and 32P-ATP incorporation into c-Mos protein or the substrate of glutathione S-transferase mitogen-activated protein kinase kinase, respectively. Both induction and activation were clearly detected after 24 h of exposure to paclitaxel concentrations of >50 ng/ml, coinciding with drug-induced apoptosis. Mitogen-activated protein kinase activation preceded c-Mos gene induction. Paclitaxel-induced c-Mos gene expression was completely abrogated by cycloheximide and actinomycin D. Mos gene expression was also induced in SKOV3 cells that were treated with vinblastine but not in those that were treated with camptothecin, etoposide, or cisplatin. We concluded that tubulin-disturbing agents induce c-Mos gene expression and activation in SKOV3 ovarian carcinoma cells and that such an effect occurs after mitotic blockade and coincides with drug-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721872

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging.

Authors:  J P Galons; M I Altbach; G D Paine-Murrieta; C W Taylor; R J Gillies
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin.

Authors:  M Kondoh; T Usui; T Nishikiori; T Mayumi; H Osada
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

3.  Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.

Authors:  Junping Wang; Dimitry Mongayt; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2005-01       Impact factor: 5.121

4.  Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe.

Authors:  Martins Kalejs; Andrey Ivanov; Gregory Plakhins; Mark S Cragg; Dzintars Emzinsh; Timothy M Illidge; Jekaterina Erenpreisa
Journal:  BMC Cancer       Date:  2006-01-09       Impact factor: 4.430

5.  Cross-talk between signalling pathways and the multidrug resistant protein MDR-1.

Authors:  S Ding; M Chamberlain; A McLaren; L Goh; I Duncan; C R Wolf
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

Review 6.  The "virgin birth", polyploidy, and the origin of cancer.

Authors:  Jekaterina Erenpreisa; Kristine Salmina; Anda Huna; Thomas R Jackson; Alejandro Vazquez-Martin; Mark S Cragg
Journal:  Oncoscience       Date:  2014-12-17

Review 7.  Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.

Authors:  Hend M Nawara; Said M Afify; Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Biomedicines       Date:  2021-05-02

8.  Tracing of intracellular pH in cancer cells in response to Taxol treatment.

Authors:  Irina Druzhkova; Maria Lukina; Varvara Dudenkova; Nadezhda Ignatova; Ludmila Snopova; Alena Gavrina; Lyubov Shimolina; Vsevolod Belousov; Elena Zagaynova; Marina Shirmanova
Journal:  Cell Cycle       Date:  2021-07-25       Impact factor: 5.173

9.  Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer.

Authors:  Jin Zhou; Yuan-Yuan Jiang; Hai-Ping Wang; Huan Chen; Yi-Chao Wu; Long Wang; Xiang Pu; Guizhou Yue; Li Zhang
Journal:  Ann Transl Med       Date:  2020-06

10.  PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells.

Authors:  Jung-Hwan Park; Sang-Ah Park; Young-Ju Lee; Hwan-Woo Park; Sang-Muk Oh
Journal:  FEBS Open Bio       Date:  2020-04-14       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.